Feb 18, 2026NMN vs NR vs Nicotinamide: First Direct Human Comparison of NAD+ PrecursorsA 2025 Nature Metabolism crossover trial directly compared NMN, NR, and nicotinamide in healthy adults. NMN and NR produced sustained blood NAD+ increases of 130–150%; nicotinamide produced only a transient 4-hour rise. Gut microbiome conversion was a key mechanistic finding.
Feb 17, 2026NAD+ Precursor Supplementation and Cognitive Fatigue: Mechanism and Human EvidenceNAD+ precursors reliably elevate blood NAD+ in humans and activate mitochondrial energy pathways. Whether this translates to clinically meaningful reductions in cognitive fatigue requires larger, longer trials.
Feb 10, 2026NMN and Brain Aging: Preclinical Signal and Human Trial UncertaintyNMN is a NAD+ precursor with strong mechanistic rationale and preclinical signal, but current human cognition data remain mixed and incomplete.
Feb 9, 2026NAD+ Booster Comparison: NMN vs NR vs Nicotinamide — Absorption, Price, Evidence, and Practical ChoiceThree main NAD+ precursors dominate the market: NMN, NR, and nicotinamide (NAM). Each enters the NAD+ biosynthetic pathway at different points. Human trial data exist for all three. Cost and evidence quality vary substantially. This practical comparison helps readers choose rationally.
Jan 31, 2026NMN vs NR vs Niacin: NAD+ Precursor Comparison, Human Data, and Practical ChoiceNMN and NR both raise NAD+ levels in humans, but mechanistic differences, tissue-specific uptake, and cost vary significantly. Head-to-head human data are limited. This article compares the available evidence and practical considerations for choosing a NAD+ precursor.